(Q42474545)

1 November 2017

Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma (English)

1 reference

1 November 2017

S Cannavò

1

1 reference

1 November 2017

L Curtò

2

1 reference

1 November 2017

S Squadrito

3

1 reference

1 November 2017

B Almoto

4

1 reference

1 November 2017

A Vieni

5

1 reference

1 November 2017

F Trimarchi

6

1 reference

1 November 2017

1 May 1999

1 reference

Journal of Endocrinological Investigation

1 November 2017

1 reference

1 November 2017

22

1 reference

1 November 2017

5

1 reference

1 November 2017

354-359

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03343573

1 November 2017

0 references

cites work

Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

Resistance to bromocriptine in prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

Pregnancy and the hyperprolactinemic woman

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

Pregnancy outcome after treatment with the ergot derivative, cabergoline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

Size Reduction of Macroprolactinomas by Bromocriptine or Lisuride Treatment*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343573

Cabergoline in the long-term therapy of hyperprolactinemic disorders.

21 January 2018

1 reference

12 December 2020

Treatment of macroprolactinoma with cabergoline: a study of 85 patients

1 reference

12 December 2020

Dopamine agonists and pituitary tumor shrinkage

1 reference

12 December 2020

CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion

1 reference

12 December 2020

Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration

1 reference

12 December 2020

Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride

1 reference

12 December 2020

Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride

1 reference

12 December 2020

Parenteral bromocriptine in the treatment of hormonally active pituitary tumours

1 reference

12 December 2020

Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine

1 reference

12 December 2020

Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients

1 reference

12 December 2020

Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline

1 reference

12 December 2020

Cabergoline: long-acting oral treatment of hyperprolactinemic disorders

1 reference

12 December 2020

Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.

1 reference

12 December 2020

Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03343573

1 reference

Dimensions Publication ID

1 November 2017

0 references

1 reference